Events temporarily associated with anti-influenza A (H1N1) vaccination in Mexico

Archives of Medical Research
Patricia VidalVesta L Richardson


In Mexico from December 2009 to June 2010, 45,490,501 doses of the vaccine against the influenza virus were administered; 27,048,330 of those corresponded to influenza A (H1N1) and 18,442,171 to seasonal influenza. Therefore, the assessment of events temporarily associated with vaccination (ETAV) is mandatory. The database corresponding to the ETAV associated with influenza (A [H1N1] and seasonal) immunization reported between December 2009 and June 2010 was analyzed. Patients who displayed at least one ETAV with one of the following schedules were included: A) influenza A (H1N1) vaccine, B) seasonal influenza vaccine, C) influenza A (H1N1) vaccine and seasonal influenza vaccine. A total of 597 ETAVs were reported. The 20- to 49-year-old age group was the most affected one (52.9%). The ETAV notification rate for influenza A (H1N1) vaccination was 1.41/100,000 applied doses vs. 0.74/100,000 applied doses corresponding to the seasonal influenza vaccination. Fifty seven events were considered serious (14 corresponded to Guillain-Barré syndrome) and these were considered coincidental unrelated events. There is no evidence of an increased rate of Guillain-Barré Syndrome with respect to the cases expected in the general population.


Mar 23, 2010·Archives of Medical Research·Alejandra Esteves-JaramilloCarlos Del Rio
Mar 25, 2010·JAMA : the Journal of the American Medical Association·Bridget M Kuehn
Jul 28, 2010·PloS One·José M Aguilar-YáñezMario M Alvarez
Nov 4, 2010·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Kunal J RambhiaEric Toner
Dec 17, 2010·The New England Journal of Medicine·Jiang WuYing Deng

Related Concepts

Trivalent Live Attenuated Influenza Vaccine
Influenza A Virus, H1N1 Subtype
Guillain-Barre Syndrome
Influenza virus vaccine
Influenza A virus
Satellite Viruses
Influenza Vaccination

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.